Apellis Pharma…
ProfileJobs

Apellis Pharmaceuticals

Suggest Edit
    • Healthbiotechdrug developmentpharma
    Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
    Market capitalization(2018-06-22)
    $1.2 B
    Type
    Public
    HQ
    Crestwood, US
    Founded
    2008
    Size (employees)
    32 (est)
    Website
    apellis.com
    Apellis Pharmaceuticals was founded in 2008 and is headquartered in Crestwood, US
    Report incorrect company information

    Key People/Management at Apellis Pharmaceuticals

    Cedric Francois

    Cedric Francois

    President and CEO
    Mike Yeadon

    Mike Yeadon

    Chief Scientific Officer
    Pascal Deschatelets

    Pascal Deschatelets

    Founder & Chief Operating Officer

    Apellis Pharmaceuticals Office Locations

    Apellis Pharmaceuticals has offices in Waltham, Cambridge, San Francisco and Crestwood
    Crestwood, US (HQ)
    6400 Westwind Way
    Cambridge, US
    1218 Massachusetts Ave
    San Francisco, US
    300 41 Grant Ave
    Waltham, US
    200 5th Ave
    Show all (4)
    Report incorrect company information

    Apellis Pharmaceuticals Financials and Metrics

    Apellis Pharmaceuticals Financials

    USD

    EBIT (Q1, 2018)

    		(21.4 m)

    Market capitalization (22-Jun-2018)

    		1.2 b

    Closing share price (22-Jun-2018)

    		21.8

    Cash (31-Mar-2018)

    		152.9 m
    Apellis Pharmaceuticals's current market capitalization is $1.2 b.
    Annual
    USDFY, 2017

    Cash

    		175.6 m

    Current Assets

    		182 m

    Total Assets

    		182.1 m

    Accounts Payable

    		3.7 m
    Quarterly
    USDQ1, 2018

    Cash

    		152.9 m

    Current Assets

    		163.1 m

    Total Assets

    		163.2 m

    Accounts Payable

    		4.6 m
    show all
    Annual
    USDFY, 2017

    Net Income

    		(51 m)

    Accounts Payable

    		932.3 k

    Cash From Operating Activities

    		(46.6 m)

    Cash From Financing Activities

    		197.4 m
    Quarterly
    USDQ1, 2018

    Net Income

    		(21.7 m)

    Accounts Payable

    		921.8 k

    Cash From Operating Activities

    		(22.9 m)

    Cash From Financing Activities

    		222.7 k
    show all
    USDY, 2018

    Financial Leverage

    		1.3 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Inovio Pharmaceuticals
    Health - Public
    Vertex Pharmaceuticals
    Health - Public
    MyoKardia
    Health - Public
    Athersys
    Health - Public
    Compare competitors

    Apellis Pharmaceuticals Online and Social Media Presence

    Embed Graph
    Report incorrect company information
    Download PDF